HAMILTON, N.J., July 27, 2011 — Medical Diagnostic Laboratories, L.L.C. (MDL) is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections.
MDL, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible in the New York, New Jersey, and Pennsylvania area.
Provided and supported by Femeris Women's Health Research Center™, established by MDL to translate women's health research into diagnostic tools, the Bacterial Vaginosis (with Lactobacillus Profiling) qPCR Panel is only available through MDL. Generally, molecular diagnostic tests for Bacterial Vaginosis (BV) are focused on the detection of recognized pathogenic markers of the disease. Incorporation of the Lactobacillus qPCR assays makes their test considerably more comprehensive and greatly extends the diagnostics available for the assessment of vaginal health.
This new Bacterial Vaginosis (with Lactobacillus Profiling) qPCR Panel marks a significant advancement beyond the qualitative identification of BV-associated microorganisms since it now covers microbial markers of the normal vaginal environment. This assay offers an opportunity for physicians to monitor the efficacy of antimicrobial therapy by evaluating dynamic changes in bacterial composition during the course of treatment and post-treatment as well as recurrence of BV due to re-infection with BV-associated microorganisms. Treatment regimens can therefore be appropriately adjusted to achieve an efficient cure.
According to Dr. Eli Mordechai, Chief Executive Office (CEO), "The Lactobacillus Profiling test is an example of a tailored molecular diagnostic approach to address chronic persistent, complex disease. This test provides the physician with additional unique valuable data that is essential in a patient's stratification, therapy and prognosis. MDL's selective molecular testing platforms are specifically designed to address complex chronic persistent disease well beyond the identification of a specific pathogen, by incorporating factors such as molecular drug resistance profiles and genetic surrogate markers."
To find out more, please visit .
Contact:
Scott Gygax, Ph.D.
Email
609.570.1015
# # #